Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN).
Bonnie S. Glisson
Research Funding - ImClone Systems
Jennifer Tseng
Research Funding - Lilly
Shanthi Marur
Research Funding - Bristol-Myers Squibb
Dong M Shin
No relevant relationships to disclose
Barbara A. Murphy
Research Funding - ImClone Systems
Ezra E.W. Cohen
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Biodesix
Christopher Y. Thomas
No relevant relationships to disclose
Richard Willey
Employment or Leadership Position - ImClone Systems
Stock Ownership - ImClone Systems
Jan Cosaert
Employment or Leadership Position - ImClone Systems
Honoraria - ImClone Systems
William Nassib William
Research Funding - Astellas Pharma; Lilly; Sanofi
Nusrat Harun
No relevant relationships to disclose
J. Jack Lee
No relevant relationships to disclose
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - Boehringer Ingelheim